VR Logo

Cyclacel Pharmaceuticals Inc. (CYCC) download report


Healthcare | Biotechnology & Pharma Research

Cyclacel Pharmaceuticals Inc. (CYCC) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases.

IPO Date: 05-May-2004

Pres, CEO & Exec. Director: Mr. Spiro George Rombotis

Exec. VP of Fin., CFO, COO, Sec. & Exec. Director: Mr. Paul McBarron

Listing: NASDAQ: CYCC

Country: United States

Headquarters: Berkeley Heights, NJ

Website: https://www.cyclacel.com

Key Facts

Market cap: $13.89 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-19.72 Mln

Cash: $29.64 Mln

Total Debt: $0.00 Mln

Insider's Holding: 4.61%

Liquidity: Low

52 Week range: $1.05 - 6.19

Shares outstanding: 9,994,990

10 Years Aggregate:

  • CFO: $-123.59 Mln
  • EBITDA: $-130.98 Mln
  • Net Profit: $-118.78 Mln

Stock Performance

Time Period Cyclacel Pharmaceuticals (CYCC) S&P BSE Sensex S&P Small-Cap 600
YTD-61.18-8.97-19.67
1 month24.79-3.38-9.84
3 months-52.06-7.93-15.05
1 Year-76.480.55-18.10
3 Years-48.1110.415.71
5 Years-55.0011.455.53
10 Years-46.3412.0510.04
As on 29-Jun-2022
Year Cyclacel Pharmaceuticals (CYCC) S&P Small-Cap 600 S&P BSE Sensex
2021-50.1925.2721.99
2020-41.729.5715.75
201910.7420.8614.38
2018-65.03-9.705.87
2017-67.1111.7327.91
2016-11.7124.741.95
2015-28.56-3.36-5.03